• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The Merlini, Waldenström, Jayakar staging system revisited.

作者信息

Merlini G, Gobbi P G, Ascari E

出版信息

Eur J Haematol Suppl. 1989;51:105-10. doi: 10.1111/j.1600-0609.1989.tb01501.x.

DOI:10.1111/j.1600-0609.1989.tb01501.x
PMID:2697581
Abstract

At present, none of the routinely used staging systems is entirely satisfactory, since all of them require some reconsideration to account for the most recent prognostic factors. Among these, serum beta-2 microglobulin (S-beta-2M) has proved to be a powerful prognostic test assessable in most centers. In order to improve the Merlini, Waldenström, Jayakar (MWJ) staging system, we have determined the prognostic significance of several factors in an independent population of 345 retrospective myeloma patients seen at our institution from 1973 to 1988. The Cox regression hazards method showed that S-Creatinine, S-Albumin levels and percentage of bone marrow plasma cells accounted for 94% of total chi 2 achieved with all eight variables (including also: paraprotein index, S-Calcium, S-M-component, bone lesions and hemoglobin). The same analysis, applied to patients in whom S-beta-2M was available at presentation, selected S-beta-2M, S-Creatinine and percentage of bone marrow plasma cells (accounting for 92% of total chi 2), followed by platelet count, S-Albumin and S-M-component. The best discriminatory level of S-beta-2M was found to be 4 mg/l. However, the prognostic power of S-beta-2M when used with binary values was remarkably reduced with respect to its application as a continuous variable. In patients with MWJ stage 1 and 2 disease, S-beta-2M had an independent prognostic significance. Grouping stage I and II patients with S-beta-2M less than or more than 4 mg/l presented a median survival of 70 and 40 months, respectively. In stage 3 patients S-beta-2M did not contribute additional prognostic information.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
The Merlini, Waldenström, Jayakar staging system revisited.
Eur J Haematol Suppl. 1989;51:105-10. doi: 10.1111/j.1600-0609.1989.tb01501.x.
2
Prognostic factors and staging in multiple myeloma: a reappraisal.多发性骨髓瘤的预后因素与分期:重新评估
J Clin Oncol. 1986 Jan;4(1):80-7. doi: 10.1200/JCO.1986.4.1.80.
3
A plea to overcome the concept of "staging" and related inadequacy in multiple myeloma.呼吁克服多发性骨髓瘤中“分期”概念及相关不足。
Eur J Haematol. 1991 Mar;46(3):177-81. doi: 10.1111/j.1600-0609.1991.tb01273.x.
4
Prognostic value of the staging system proposed by Merlini, Waldenström and Jayakar for multiple myeloma.梅林尼、瓦尔登斯特伦和贾亚卡尔提出的分期系统对多发性骨髓瘤的预后价值。
Acta Haematol. 1983;70(6):379-85. doi: 10.1159/000206796.
5
Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.血清β2微球蛋白和血清胸苷激酶是慢性淋巴细胞白血病和免疫细胞瘤无进展生存期的独立预测指标。
Leuk Lymphoma. 1996 Aug;22(5-6):439-47. doi: 10.3109/10428199609054782.
6
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.浆细胞标记指数和β2-微球蛋白可独立于胸苷激酶和C反应蛋白预测多发性骨髓瘤的生存期。
Blood. 1993 Jun 15;81(12):3382-7.
7
A new staging system for multiple myeloma based on the number of S-phase plasma cells.一种基于S期浆细胞数量的多发性骨髓瘤新分期系统。
Blood. 1995 Jan 15;85(2):448-55.
8
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.利用游离β2微球蛋白的HLA I类重链血清水平以及IgM或血小板计数对活动性疾病的多发性骨髓瘤患者进行分期。
Blood Cells Mol Dis. 2009 Jan-Feb;42(1):71-6. doi: 10.1016/j.bcmd.2008.09.003. Epub 2008 Nov 7.
9
Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.β2-微球蛋白水平和浆细胞标记指数作为新诊断骨髓瘤患者预后因素的价值
Blood. 1988 Jul;72(1):219-23.
10
Serum beta 2-microglobulin at remission and relapse in patients with multiple myeloma.多发性骨髓瘤患者缓解期和复发期的血清β2微球蛋白
Eur J Clin Invest. 1985 Oct;15(5):242-7. doi: 10.1111/j.1365-2362.1985.tb00177.x.